Boston Scientific Corporation (BSX) Earnings
Boston Scientific Corporation is expected to report next earnings on July 29, 2026 (in NaN days), with a consensus EPS estimate of $0.83. BSX has beaten EPS estimates in 11 of its last 12 reported quarters (average surprise +3.1% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 22, 2026 | $0.79 | $0.80 | +1.5% | $5.2B | +0.6% |
| Feb 4, 2026 | $0.78 | $0.80 | +2.4% | $5.3B | +0.1% |
| Oct 22, 2025 | $0.71 | $0.75 | +5.0% | $5.1B | +1.9% |
| Jul 23, 2025 | $0.72 | $0.75 | +3.4% | $5.1B | +3.4% |
| Apr 23, 2025 | $0.67 | $0.75 | +11.4% | $4.7B | +2.0% |
| Feb 5, 2025 | $0.66 | $0.70 | +6.5% | $4.6B | +3.2% |
| Oct 23, 2024 | $0.59 | $0.63 | +7.1% | $4.2B | +4.2% |
| Jul 24, 2024 | $0.58 | $0.62 | +6.3% | $4.1B | +2.3% |
| Jan 31, 2024 | $0.51 | $0.55 | +7.8% | $3.7B | +3.7% |
| Oct 26, 2023 | $0.48 | $0.50 | +4.2% | $3.5B | +1.5% |
| Jul 27, 2023 | $0.49 | $0.53 | +8.2% | $3.6B | +2.8% |
| Feb 1, 2023 | $0.47 | $0.45 | -4.3% | $3.2B | -0.0% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · April 22, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
• First quarter was solid with 9.4% organic sales growth, 6% adjusted EPS growth, 28% adjusted operating margin. • 2026 has been more challenging, guiding 5%-7% organic growth for Q2 and reducing full-year guidance to 6.5%-8%. • Regionally, U.S. grew 11%, Europe and Middle East Africa 1%, AsiaPAC 12%. • Business units: Urology had tough Q1, expect improvement; Endoscopy grew 7%; Neuromodulation strong; Cardiovascular grew 11%; Interventional oncology grew 15%; Cardiac rhythm management declined; Watchman grew 19% but outlook adjusted; EP grew 22% but outlook adjusted. • Mentioned acquisitions like Valencia Technologies and pending Penumbra acquisition
Guidance
• Full-year 2026 reported revenue growth expected 7.0%-8.5%, operational and organic growth 6.5%-8.0%. • Q2 2026 reported revenue growth expected 5.5%-7.5%, operational and organic growth 5.0%-7.0%. • Full-year 2026 adjusted EPS expected $3.34-$3.41, growth 9%-11%. • Q2 adjusted EPS expected $0.82-$0.84. • Guidance excludes Penumbra acquisition closing
Segment performance
Total company organic sales growth 9.4% in Q1. U.S. grew 11% with double-digit growth in five out of eight business units. Europe and Middle East Africa grew 1% operationally. AsiaPAC grew 12% operationally. Urology had 1% organic sales growth in Q1, expected low to mid-single digits full-year. Endoscopy sales grew 7% organically. Neuromodulation organic sales grew 15%. Cardiovascular-delivered organic sales grew 11%. Interventional oncology organic sales grew 15%. Cardiac rhythm management sales declined 3% in Q1. Watchman grew 19% organically in Q1, expected global mid-teens growth full-year. EP organic sales grew 22%, expected global ~10% growth full-year with U.S. mid-single-digit and international ~20% growth
Risks & headwinds
• Unanticipated headwinds and changing business patterns impacting growth. • Increased competition in certain markets like EP affecting share. • Commercial disruptions in urology's sacral neuromodulation business. • Evolving practice patterns and reimbursement dynamics impacting Watchman growth. • Risks related to forward-looking statements and potential material differences from projections
Analyst Q&A
Q: Asked about what prompted the guidance lowering, impact of Watchman, EP, urology.
A: Mike discussed contributors to guide down like Watchman's declining trend, EP share erosion, urology's tough quarter.
Q: Asked about quarters ahead for EP, Watchman, urology.
A: Said Q2 is toughest quarter, with Watchman and EP having challenging comps, urology expected to improve in second half.
Q: Asked about EP market share and outlook.
A: Said global EP expected ~10% growth, U.S. mid-single-digit, international ~20%, with increased competition but confidence in PFA leadership.
Q: Asked about Watchman outlook and addressing concerns.
A: Discussed factors like practice pattern changes, commercial investments, marketing to address Watchman's growth.
Q: Asked about non-EP and Watchman business.
A: Talked about Interventional Cardiology and Vascular Therapies, Interventional Oncology, MedSurge's performance and product launches.
Q: Asked about WAMGR and LRP.
A: Said WAMGR was adjusted, LRP details not yet finalized but confident in margin improvement and EPS growth.
Q: Asked about EPS guidance revision and profitability.
A: Said less margin benefit, focusing on OpEx leverage through spend controls and org structure optimization.
Q: Asked about urology's sacro-neuromodulation business.
A: Discussed commercial turnover issues and steps taken to improve.
Q: Asked about buyback and Penumbra deal.
A: Said funding buyback with cash on hand, committed to Penumbra deal.
Q: Asked about Watchman standalone growth outlook.
A: Stated global Watchman expected mid-teens growth, U.S. low to mid-single digits